Citations

Clear

1820 citation(s) found for "Israel, E".

The effect of Mankai plant consumption on postprandial glycaemic response among patients with type 2 diabetes: A randomized crossover trial
Tsaban, Gal , Aharon‐Hananel, Genya, Shalem, Shiran, Zelicha, Hila , Meir, Anat Yaskolka , Pachter, Dafna , Goldberg, D , Kamer, Omer , Alufer, Liav , Stampfer, Meir J. , Qi, Lu , Blüher, Matthias , Hu, Frank B., Shai, Iris , Qi, Lu , Blüher, Matthias , Yaskolka Meir, Anat , Shai, Iris , Goldberg, Dana Tamar , Wang, Dong D. , Stümvoll, Michael , Tirosh, Amir

Mayo Clinic

Diabetes, Obesity and Metabolism | August 12, 2024 | Volume: 26 | Issue: 10 | Pages: 4713-4723

10.1111/dom.15840 | PMID 39134456 Get It

Abstract Aim To explore the effect of Mankai, a cultivated aquatic duckweed green plant, on postprandial glucose (PG) excursions in type 2 diabetes (T2D). Methods In a 4‐week, randomized crossover‐controlled trial, we enrolled 45 adults with T2D (HbA1c range: 6.5%‐8.5%) from two sites in Israel. Participants were randomized to drink Mankai (200 mL of raw‐fresh‐aquatic plant + 100 mL of water, 40 kcal, ~10 g of dry matter equivalent) or water (300 mL) following dinner, for 2 weeks each, with a 4‐day washout interval, without dietary, physical activity or pharmacotherapy alterations. We used continuous glucose monitoring (CGM) devices. Results Forty patients (adherence rate = 88.5%; 743 person‐intervention‐days, 68.9% men, age = 64 years, HbA1c = 6.8%) completed the study with a consistent diet and complete CGM reads. Only two‐thirds of the individuals responded beneficially to Mankai. Overall, Mankai significantly lowered the PG peak by 19.3% (∆peak = 24.3 ± 16.8 vs. 30.1 ± 18.5 mg/dL; P < .001) and delayed the time‐to‐peak by 20.0% (112.5 [interquartile range: 75‐135] vs. 90 [60‐105] min; P < .001) compared with water. The PG incline and decline slopes were shallower following postdinner Mankai (incline slope: 16.8 vs. water: 29.9 mg/[dL h]; P < .001; decline slope: −6.1 vs. water: −7.9 mg/[dL h]; P < .01). Mean postprandial net incremental area‐under‐the‐glucose‐curve was lowered by 20.1% with Mankai compared with water ( P = .03). Results were consistent across several sensitivity and subgroup analyses, including across antidiabetic pharmacotherapy treatment groups. Within 2 weeks, the triglycerides/high‐density lipoprotein cholesterol ratio in the Mankai group (−0.5 ± 1.3) decreased versus water (+0.3 ± 1.5, P = .05). Conclusions Mankai consumption may mitigate the PG response in people with T2D with an ~20% improvement in glycaemic values. These findings provide case‐study evidence for plant‐based treatments in T2D to complement a healthy lifestyle and pharmacotherapy.
Racial differences of secondary metastasis in patients with colon cancer: A United States population-based cohort study.
Tribuddharat, Narisara , Lohawatcharagul, Tuntanut, Saowapa, Sakditad , Thongpiya, Jerapas , Chaisidhivej, Natapat, Suenghataiphorn, Thanathip , Kulthamrongsri, Narathorn , Danpanichkul, Pojsakorn , Osataphan, Soravis Alm

Mayo Clinic

Journal of Clinical Oncology | August 12, 2024 | Volume: 42 | Issue: 23_suppl | Pages: 80-80

10.1200/jco.2024.42.23_suppl.80 Get It

80 Background: Disparities in health outcomes exist among racial and ethnic groups in the United States, notably in patients with colon cancer. Metastasis is the primary cause of cancer morbidity and mortality. However, data on the metastasis risks and clinical outcomes on hospitalized individuals with colon cancer is still limited. Therefore, we aim to assess the association between metastatic colon cancer and racial differences. Methods: We analyzed the 2020 U.S. National Inpatient Sample (NIS) to explore patients who have colon cancer as the primary diagnosis. Additionally, we identified evidence of metastasis, as recorded by ICD-10-CM. Adjusted odds ratios (aORs) for specified outcomes were calculated through multivariable logistic and linear regression analyses. The primary outcome was racial differences in organ metastasis and secondary outcomes included mortality and length of stay. Statistical significance was established at p-value of 0.05. Results: We identified 80,130 patients with primary diagnosis of colon cancer at discharge. The mean age was 67.4 years; 49.7% were female. Caucasians accounted for 69.3%, with African Americans at 13.3% and Hispanics at 8.2%. 15% of the patients had liver metastasis, whereas 22% had lung metastasis. In a multivariate analysis adjusting for patient, COVID-19, chemotherapy usage and hospital factors, African Americans had higher risk of lung metastasis (aOR 1.22; 95%CI (1.07, 1.40), p = 0.003), higher risk of liver metastasis (aOR 1.51; 95%CI (1.31, 1.74), p = 0.021) and longer length of stay (b = 0.95; 95%CI (0.56, 1.33), p = 0.001). Hispanics also had higher risk of lung (aOR 1.22, p < 0.05) and liver metastasis (aOR 1.24, p = 0.021). We observed an increase in risk of metastasis and mortality but non-statistically significant in some parameters and races, as shown in table provided. Conclusions: In conclusion, our study revealed that racial difference is associated with higher risk of metastasis, as well as other outcomes. To establish a causal relationship between races, metastasis, and mortality in patients with colon cancer, further longitudinal research is necessary. [Table: see text]
Racial impact of secondary metastasis in patients with lung cancer: Evidence of US hospitals in 2020.
Saowapa, Sakditad , Naunsilp, Piengpitch, Xanthavanij, Nutchapon , Suenghataiphorn, Thanathip , Kulthamrongsri, Narathorn , Osataphan, Soravis Alm

Mayo Clinic

Journal of Clinical Oncology | August 12, 2024 | Volume: 42 | Issue: 23_suppl | Pages: 213-213

10.1200/jco.2024.42.23_suppl.213 Get It

213 Background: Lung cancer patient often encounter disparities in health outcomes, especially in difference racial and ethnic groups. Metastasis is the primary cause of cancer morbidity and mortality. However, data on the metastasis risks and clinical outcomes on hospitalized individuals with lung cancer is still limited. Therefore, we aim to assess the association between metastatic lung cancer and racial differences. Methods: We analyzed the 2020 U.S. National Inpatient Sample (NIS) to explore patients who have lung cancer as the primary diagnosis. Additionally, we identified evidence of metastasis, as recorded by ICD-10-CM. Adjusted odds ratios (aORs) for specified outcomes were calculated through multivariable logistic and linear regression analyses. The primary outcome was racial differences in organ metastasis and secondary outcomes included mortality and length of stay. Statistical significance was established at p-value of 0.05. Results: We identified 103,335 patients with primary diagnosis of lung and bronchus cancer at discharge. The mean age was 68.9 years; 50.5% were female. Caucasians accounted for 74.3%, with African Americans at 12.1% and Hispanics at 4.6%. 10% of the patients had brain metastasis, whereas 14% had bone metastasis. In a multivariate analysis adjusting for patient, COVID-19, chemotherapy usage and hospital factors, African Americans had higher risk of brain metastasis (aOR 1.18; 95%CI (1.02, 1.37), p = 0.002), higher risk of bone metastasis (aOR 1.16; 95%CI (1.02, 1.33), p = 0.025), higher risk of mortality (aOR 1.21; 95% CI (1.01, 1.45), p = 0.039) and longer length of stay (b = 0.85; 95%CI (0.55, 1.16), p = 0.001). Hispanics also had higher risk of brain (aOR 1.36, p < 0.05) and prolonged length of stay (b 0.79, p < 0.005). We observed an increase in risk of metastasis and mortality but non-statistically significant in some parameters and races, as shown in table provided. Conclusions: In conclusion, our study revealed that racial difference is associated with higher risk of metastasis, as well as other outcomes. Further longitudinal research is necessary to establish a causal relationship between races, metastasis, and mortality in patients with lung cancer. [Table: see text]
Mortality and economic cost in common primary cancer admitted with COVID-19: Analysis of NIS 2020.
Srikulmontri, Thitiphan , Xanthavanij, Nutchapon , Tribuddharat, Narisara , Buasri, Kochakorn , Saowapa, Sakditad , Lohawatcharagul, Tuntanut, Suenghataiphorn, Thanathip , Wattanachayakul, Phuuwadith , Kulthamrongsri, Narathorn , Danpanichkul, Pojsakorn , Osataphan, Soravis Alm

Mayo Clinic

Journal of Clinical Oncology | August 12, 2024 | Volume: 42 | Issue: 23_suppl | Pages: 182-182

10.1200/jco.2024.42.23_suppl.182 Get It

182 Background: Recent data showed the detrimental effects of COVID-19 infection on various conditions, resulting in a wide range of health disparities and worsening outcomes, as well as an increased burden of cost. However, limited information exists on the impacts of COVID-19 infection on the most commonly admitted with primary cancer, regarding clinical and economic impact. Methods: We analyzed the 2020 U.S. National Inpatient Sample (NIS) to investigate the effects of COVID-19 infection on cases primarily admitted with the most common admitted with primary cancer, using relevant ICD-10 CM codes. Adjusted odds ratios (aORs) for specified outcomes were calculated through multivariable logistic and linear regression analyses. The primary outcome was inpatient mortality, with secondary outcomes including the cost of hospitalization and length of stay. Statistical significance was established at a p-value of 0.05. Results: We estimated 919,104 hospitalizations with a primary discharge diagnosis of cancer conditions. Of these, 0.54% (4,985/919,104) had a concurrent diagnosis of COVID-19 infection and 46.1% were female. The mean age was 63.6 years old and Caucasians dominated the majority of the records (69.7%), followed by Hispanics (13.1%). In a multivariable logistic and linear regression model adjusting for patient and hospital factors, COVID-19 infection was associated with higher in-hospital mortality for all cancer conditions and other outcome. The txable denotes all-type and subpopulation analysis. Conclusions: In conclusion, our study encompasses all most common admitted primary cancer conditions and shed light how COVID-19 infection is associated with higher in-hospital mortality, prolonged hospital stays, and increased economic burden in various condition. Future longitudinal studies are warranted to comprehensively assess the long-term health sequelae in this population. [Table: see text]
International Headache Society global practice recommendations for the acute pharmacological treatment of migraine
Puledda, Francesca , Diener, Hans‐Christoph , Al‐Khazali, Haidar M. , Ashina, Sait , Liebler, Eric , Chu, Min Kyung , Cocores, Alexandra, Dodd-Glover, Freda , Ekizoğlu, Esme , Göbel, Carl, Hassan, Amr , Hirata, Koichi , Hoffmann, Jan , Jenkins, Bronwyn , Kamm, Katharina , Martinelli, Daniele , Monteith, Teshamae , Romanenko, V.I. , Vandenbussche, Nicolas , Tassorelli, Cristina , Diener, Hans-Christoph , Ashina, Sait , Chu, Min Kyung , Garcia-Azorin, David , Hoffmann, Jan , Kamm, Katharina , Lee, Mi Ji , Ling, Yu-Hsiang , Martinelli, Daniele , Monteith, Teshamae S , Ornello, Raffaele , Rozen, Todd D. , Pozo-Rosich, Patricia , Souza, Marcio Nattan P , Thuraiaiyah, Janu , Togha, Mansoureh , Wang, Shuu-Jiun , Yu, Shengyuan , Tassorelli, Cristina , Al-Khazali, Haidar M , Puledda, Francesca , Hassan, Amr , Sacco, Simona , Ashina, Messoud , Burstein, Rami , Cipriani, Andrea , Göbel, Carl Hartmut , Goicochea, María Teresa , Lee, Mi Ji , Lisicki, Marco , Ornello, Raffaele , Özge, Aynur , Peres, Mário Fernando Prieto , Pozo‐Rosich, Patricia , Schwedt, Todd J. , Takizawa, Tsubasa , Terwindt, Gisela M. , Wang, Shuu‐Jiun

Mayo Clinic

Cephalalgia | August 12, 2024 | Volume: 44 | Issue: 8 | Pages: No page available

10.1177/03331024241252666 | PMID 39133176 Get It

Background In an effort to improve migraine management around the world, the International Headache Society (IHS) has here developed a list of practical recommendations for the acute pharmacological treatment of migraine. The recommendations are categorized into optimal and essential, in order to provide treatment options for all possible settings, including those with limited access to migraine medications. Methods An IHS steering committee developed a list of clinical questions based on practical issues in the management of migraine. A selected group of international senior and junior headache experts developed the recommendations, following expert consensus and the review of available national and international headache guidelines and guidance documents. Following the initial search, a bibliography of twenty-one national and international guidelines was created and reviewed by the working group. Results A total of seventeen questions addressing different aspects of acute migraine treatment have been outlined. For each of them we provide an optimal recommendation, to be used whenever possible, and an essential recommendation to be used when the optimal level cannot be attained. Conclusion Adoption of these international recommendations will improve the quality of acute migraine treatment around the world, even where pharmacological options remain limited.
Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa‐Induced Dyskinesia
Sosero, Yuri L. , Bandrés‐Ciga, Sara , Tocino, Maria Teresa Periñan, Belloso, Dìaz R., Gómez‐Garre, Pilar , Faouzi, Johann , Pavelka, Lukas , Marques, Tainá M. , May, Patrick , Milanowski, Łukasz , Uitti, Ryan J. , Hilten, Jacobus J. van , Simon, David K. , Eberly, Shirley , Krohn, Lynne , Freeman, Kathryn , Ruskey, Jennifer A. , Asayesh, Farnaz , Menéndez‐González, Manuel , Pástor, Pau , Ross, Owen A. , Krüger, Rejko , Kõks, Sulev, Mir, Pablo , Klucken, Jochen , Gómez‐Garre, Pilar , Fatima, Noor , Gómez-Garre, Pilar , May, Patrick , Milanowski, Łukasz M , Wszolek, Z.K. , Simon, David K , Ross, Owen A , Corvol, Jean-Christophe , Koks, Sulev , Mir, Pablo , de Bie, Rob M A , Iwaki, Hirotaka , Gan-Or, Ziv , Pastor, Pau , Ferwerda, Bart , Taba, Pille , Gomes, Clarissa P. C. , Kolodkin, Alexey N. , Wszołek, Zbigniew K. , Heutink, Peter , Álvarez, Ignacio , Yu, Eric , Freeman, Kathryn, Rudakou, Uladzislau , Corvol, Jean‐Christophe , Bie, Rob M.A. de , Gan‐Or, Ziv

Mayo Clinic

Movement Disorders | August 12, 2024 | Volume: 39 | Issue: 10 | Pages: 1773-1783

10.1002/mds.29960 | PMID 39132902 Get It

Abstract Background Levodopa‐induced dyskinesia (LID) is a common adverse effect of levodopa, one of the main therapeutics used to treat the motor symptoms of Parkinson's disease (PD). Previous evidence suggests a connection between LID and a disruption of the dopaminergic system as well as genes implicated in PD, including GBA1 and LRRK2 . Objectives Our goal was to investigate the effects of genetic variants on risk and time to LID. Methods We performed a genome‐wide association study (GWAS) and analyses focused on GBA1 and LRRK2 variants. We also calculated polygenic risk scores (PRS) including risk variants for PD and variants in genes involved in the dopaminergic transmission pathway. To test the influence of genetics on LID risk we used logistic regression, and to examine its impact on time to LID we performed Cox regression including 1612 PD patients with and 3175 without LID. Results We found that GBA1 variants were associated with LID risk (odds ratio [OR] = 1.65; 95% confidence interval [CI], 1.21–2.26; P = 0.0017) and LRRK2 variants with reduced time to LID onset (hazard ratio [HR] = 1.42; 95% CI, 1.09–1.84; P = 0.0098). The fourth quartile of the PD PRS was associated with increased LID risk (OR fourth_quartile = 1.27; 95% CI, 1.03–1.56; P = 0.0210). The third and fourth dopamine pathway PRS quartiles were associated with a reduced time to development of LID (HR third_quartile = 1.38; 95% CI, 1.07–1.79; P = 0.0128; HR fourth_quartile = 1.38; 95% CI = 1.06–1.78; P = 0.0147). Conclusions This study suggests that variants implicated in PD and in the dopaminergic transmission pathway play a role in the risk/time to develop LID. Further studies will be necessary to examine how these findings can inform clinical care. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Application of the international criteria for optic neuritis in the Acute Optic Neuritis Network
Klyscz, Philipp , Asseyer, Susanna , Bereuter, Charlotte , Bialer, Omer , Bick, Atira, Carta, Sara , Chen, John J. , Cohen, Leila , Cohen‐Tayar, Yamit , Gernert, Jonathan A. , Haas, Julian , Heesen, Christoph , Hellmann, Mark A. , Levin, Netta , Lotan, Itay , Luis, María Belén , Vergara, Alvaro Jose Mejia, Ocampo, Cassandra, Ochoa, Susana, Oertel, Frederike Cosima , Olszewska, Maja, Uribe, José Luis Peralta , Scocco, Darío H. , Shifa, Jemal Zeberga, Simantov, Ilya, Tiosano, Alon , Torres-Camacho, Isabel , Dembinsky, Adi Vaknin, Vidal‐Jordana, Ángela , Wilf‐Yarkoni, Adi , Wu, Ti , Zamir, Sol, Zarco, Luis Alfonso , Zimmermann, Hanna , Paul, Friedemann , Dale, Russell C , Levin, Netta , Lotan, Itay , Mariotto, Sara , Oertel, Frederike C , Sastre-Garriga, Jaume , Ramanathan, Sudarshini , Rattanathamsakul, Natthapon , Shi, Fu-Dong , Tisavipat, Nanthaya , Zimmermann, Hanna G , Paul, Friedemann , Chen, John J , Carta, Sara , Alonso, Ricardo Nicolás , Contentti, Edgar Carnero , Dale, Russell C. , Flanagan, Eoin P. , Haas, Julian, Havla, Joachim , López, Pablo A. , Mariotto, Sara , Mayer, Christina , Mejía-Vergara, Álvaro J. , Ramanathan, Sudarshini , Rattanathamsakul, Natthapon , Siritho, Sasitorn , Tisavipat, Nanthaya , Petzold, Axel , Stiebel‐Kalish, Hadas

Mayo Clinic

Annals of Clinical and Translational Neurology | August 5, 2024 | Volume: 11 | Issue: 9 | Pages: 2473-2484

10.1002/acn3.52166 | PMID 39099240 Get It

AbstractObjectiveThe first international consensus criteria for optic neuritis (ICON) were published in 2022. We applied these criteria to a prospective, global observational study of acute optic neuritis (ON).MethodsWe included 160 patients with a first‐ever acute ON suggestive of a demyelinating CNS disease from the Acute Optic Neuritis Network (ACON). We applied the 2022 ICON to all participants and subsequently adjusted the ICON by replacing a missing relative afferent pupillary defect (RAPD) or dyschromatopsia if magnetic resonance imaging pathology of the optical nerve plus optical coherence tomography abnormalities or certain biomarkers are present.ResultsAccording to the 2022 ICON, 80 (50%) patients were classified as definite ON, 12 (7%) patients were classified as possible ON, and 68 (43%) as not ON (NON). The main reasons for classification as NON were absent RAPD (52 patients, 76%) or dyschromatopsia (49 patients, 72%). Distribution of underlying ON etiologies was as follows: 78 (49%) patients had a single isolated ON, 41 (26%) patients were diagnosed with multiple sclerosis, 25 (16%) patients with myelin oligodendrocyte glycoprotein antibody‐associated disease, and 15 (9%) with neuromyelitis optica spectrum disorder. The application of the adjusted ON criteria yielded a higher proportion of patients classified as ON (126 patients, 79%).InterpretationAccording to the 2022 ICON, almost half of the included patients in ACON did not fulfill the requirements for classification of definite or possible ON, particularly due to missing RAPD and dyschromatopsia. Thorough RAPD examination and formal color vision testing are critical to the application of the 2022 ICON.
AAPM Task Group Report 299: Quality control in multi‐energy computed tomography
Leng, Shuai, Boedeker, Kirsten , Burk, Laurel M., Dang, Hao , Li, Baojun , Madhav, Priti, Miller, Jessica R. , Nute, J, Giraldo, Juan Carlos Ramírez, Ruchala, Kenneth J., Tao, Shengzhen , Varchena, Vladimir, Vedantham, Srinivasan , Zeng, Rongping , Layman, Rick R. , Leng, Shuai , Duan, Xinhui , Jacobsen, Megan C. , Li, Ke , Little, Kevin J. , Ruchala, Ken, Zhang, Da

Mayo Clinic

Medical Physics | July 29, 2024 | Volume: 51 | Issue: 10 | Pages: 7012-7037

10.1002/mp.17322 | PMID 39072826 Get It

AbstractMulti‐energy computed tomography (MECT) offers the opportunity for advanced visualization, detection, and quantification of select elements (e.g., iodine) or materials (e.g., fat) beyond the capability of standard single‐energy computed tomography (CT). However, the use of MECT requires careful consideration as substantially different hardware and software approaches have been used by manufacturers, including different sets of user‐selected or hidden parameters that affect the performance and radiation dose of MECT. Another important consideration when designing MECT protocols is appreciation of the specific tasks being performed; for instance, differentiating between two different materials or quantifying a specific element. For a given task, it is imperative to consider both the radiation dose and task‐specific image quality requirements. Development of a quality control (QC) program is essential to ensure the accuracy and reproducibility of these MECT applications. Although standard QC procedures have been well established for conventional single‐energy CT, the substantial differences between single‐energy CT and MECT in terms of system implementations, imaging protocols, and clinical tasks warrant QC tests specific to MECT. This task group was therefore charged with developing a systematic QC program designed to meet the needs of MECT applications. In this report, we review the various MECT approaches that are commercially available, including information about hardware implementation, MECT image types, image reconstruction, and postprocessing techniques that are unique to MECT. We address the requirements for MECT phantoms, review representative commercial MECT phantoms, and offer guidance regarding homemade MECT phantoms. We discuss the development of MECT protocols, which must be designed carefully with proper consideration of MECT technology, imaging task, and radiation dose. We then outline specific recommended QC tests in terms of general image quality, radiation dose, differentiation and quantification tasks, and diagnostic and therapeutic applications.
Novel method of iliac accessory rods for rod fracture prevention in adult deformity surgery: a case series of 82 patients with outcomes and complications
Berlin, Connor , Ben‐Israel, David , Park, Brian J. , Yen, Chun-Po , Shaffrey, Mark E., Sardi, José , Ibrahim, Sufyan , Smith, Justin S.

Mayo Clinic

Journal of Neurosurgery: Spine | July 26, 2024 | Volume: 43 | Issue: 4 | Pages: 424-432

10.3171/2024.5.spine24208 | PMID 39059456 Get It

OBJECTIVE Primary rod fracture after surgery for adult spinal deformity (ASD) is a leading cause of revision, with recent prospective multicenter fracture rates reported at 11%–14% by 2 years. Consequently, the addition of supplemental rods has been explored to reduce fractures. Here the authors describe their experience with a novel iliac accessory rod technique in which each accessory rod anchors to an independent iliac bolt caudally via lateral connector, and attaches to the primary rod rostrally via side-to-side connector. METHODS This retrospective, single-center case series included patients who underwent thoracolumbar/lumbar fusion for ASD between March 2019 and August 2023. Data on baseline demographics, radiographic parameters, surgical characteristics, complications, rod fracture, and revision rates were collected. Paired, 2-tailed t-tests were used to compare pre- and postoperative radiographic outcomes. Rod fracture rates were compared to prior investigations via chi-square goodness of fit testing. The technique for iliac accessory rod placement is described. RESULTS The study consisted of 82 patients (mean age 66 years, 51% female, 26% with prior fusion) with a median follow-up of 2 years (IQR 28–104 weeks). A total of 50 patients (61%) had ≥ 2-year follow-up. Each surgery involved an average of 4 posterior column osteotomies and 8 segments. Iliac accessory rods were cobalt chromium and were placed bilaterally in 87% of constructs. Postoperative alignment improved significantly in the following parameters: maximum coronal Cobb angle, fractional curve, sagittal vertical axis, lumbar lordosis, thoracic kyphosis, and pelvic incidence to lumbar lordosis mismatch (p < 0.001 for all comparisons). Of 50 patients with ≥ 2-year follow-up, rod fracture occurred in 1 (2.0%), which was incidentally found and required no intervention. The present rod fracture rate was significantly lower than the authors’ historically reported institutional rate of 21% for traditional dual-rod constructs, and the 11%–14% reported in recent prospective multicenter studies that used traditional and supplemental rod constructs (p < 0.05 for all comparisons). Reoperation occurred in 12 patients (14.6%); 7 (8.5%) for proximal junctional kyphosis and 5 (6.1%) for wound complication. CONCLUSIONS Here the authors describe their experience with a novel iliac accessory rod technique to prevent rod fracture in patients undergoing surgery for ASD. The 2-year rod fracture rate (2.0%) in this study is significantly lower than the authors’ historical dual-rod fracture rate, and other prospective multicenter investigations. Future studies with longer follow-up are needed to determine the durability of this technique.